Workflow
嘉应制药获融资买入180.09万元,不久前被立案受损股民可索赔

Group 1 - On July 9, 2025, the company received a financing buy-in of 1.8009 million yuan, accounting for 9.49% of the total buy-in amount for the day, with a current financing balance of 237 million yuan, representing 7.23% of the circulating market value, which is below the historical 50% percentile level [2] - On May 28, 2025, the company announced that it received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to suspected violations of information disclosure laws, leading to a formal investigation [2] - Investors who purchased shares before May 28, 2025, and held them until the market close on that date may be eligible for compensation due to the company's alleged information disclosure violations [2] Group 2 - On December 12, 2024, the company’s board approved a share repurchase plan, intending to buy back between 7 million and 13.5 million shares at a maximum price of 9.8 yuan per share, with a total repurchase amount not exceeding 132.3 million yuan [3] - The company initiated its first share repurchase on January 3, 2025, and as of March 31, 2025, it had repurchased 7.1871 million shares, accounting for 1.42% of the total share capital, with a total transaction amount of 49.4693 million yuan [3][4] - The funds for the share repurchase are sourced from the company's own funds, and the repurchase price did not exceed the proposed maximum price of 9.8 yuan per share [4] Group 3 - The company holds 82 trademark registrations and 11 patents, along with 268 administrative licenses, indicating a robust intellectual property portfolio [4]